Phenylethyl isothiocyanate (PEITC), generally thought to be a chemopreventive agent for various kinds of genotoxic carcinogens, has been found to induce rat urinary bladder carcinomas in our laboratory. To cast light on the underlying mechanisms, the reversibility of urothelial proliferative lesions and the frequencies of H-ras and p53 mutations in the induced rat urinary bladder tumors were investigated. F344 male rats were given diet containing 0.1% PEITC for 48 weeks and then killed, or for 32 weeks and then returned to normal diet without supplement for 1, 3, 7 days or 16 weeks before death. At 7 days after withdrawal of PEITC treatment, carcinomas were observed in only two of 24 rats but a high incidence of dysplasias was evident. Furthermore, 16 weeks after withdrawal, seven of 12 (58.3%) rats had carcinomas. In addition, carcinomas were induced in 11 of 12 (91.7%) rats continuously receiving PEITC for 48 weeks. Most of the carcinomas were characterized as of non-papillary transitional cell type with occasional squamous cell differentiation and/or glandular components. Bromodeoxyuridine labeling indices (LIs) were increased by PEITC administration even in normallooking epithelium. After withdrawal of treatment, LIs in simple and papillary or nodular (PN) hyperplasias were markedly decreased and these lesions gradually disappeared, while values for dysplasias and carcinomas, which persisted, were only slightly decreased. A silent point mutation was found in H-ras in one of 12 tumor samples (8.3%), whereas seven (58.3%) had mutations in p53. These results indicate that PEITC itself is a carcinogen for the rat urinary bladder, and that while the simple and PN hyperplasia induced by PEITC are reversible, dysplasia is irreversible with the potential to give rise to non-papillary carcinomas with frequent p53 mutations.
Introduction
Phenylethyl isothiocyanate (PEITC) is a natural constituent of cruciferous vegetables such as cabbages, cauliflowers, Brussels sprouts and watercress (1) , and mean daily intake of gluconasturiin, a glucosinolate of PEITC, from swede-turnips in UK, is reported to be 0.8 mg/person/day (0.3 mg/person/day as PEITC) (2) . The compound is known as a natural chemopreventive agent capable of potently inhibiting carcinogenesis by various chemicals. For example, it is reported to decrease 7,12-dimethylbenz [a] anthracene-induced mammary tumor development in female Sprague-Dawley rats (when given at 0.55% in the diet) (3) , N-nitrosobenzylmethylamine-induced esophageal carcinogenesis in male F344 rats (0.005-0.08% in the diet) (4) (5) (6) , and 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanoneinduced lung tumorigenesis in F344 rats (0.04% in diet) and A/J mice (0.8 or 4 mg/day by intragastric tube) (7, 8) , when given to the animals mostly during or prior to carcinogen exposure. It may modify carcinogenesis by influencing cytochrome P-450s, which metabolize carcinogens into reactive species (9, 10) , by inhibiting microsome-mediated DNA methylation (11) , or by inducing phase II enzymes, which detoxify carcinogens (12) . In 1998, however, we demonstrated that continuous oral administration of 0.1% PEITC for 24 weeks after carcinogen exposure enhanced urinary bladder carcinogenesis in a multi-organ carcinogenesis model (13) . Subsequently, PEITC clearly enhanced the rat urinary bladder carcinogenesis (14) , with dose-dependence when rats were pre-treated with N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN) (15) . It was also found that 0.1% PEITC itself induced urinary bladder carcinomas in 33% of animals with 32 weeks administration (14) , suggesting possession of carcinogenic potential. However, this conclusion must remain provisional until mechanisms of enhancement of carcinogenesis or carcinogenic potential of PEITC are fully elucidated.
Genotoxicity of PEITC has been shown in an SV40-transformed Indian Muntjac cell line (16) and in a Chinese hamster ovary cell line (17) , as evidenced by chromosomal aberration. PEITC-genotoxicity was also recently demonstrated in the Salmonella/microsomal assay with TA 98 and TA 100, the differential DNA repair assay with Escherchia coli and the micronucleus induction assay with human derived HepG2 cells (18) . Therefore, a contribution of genotoxicity to the induction of bladder tumors by PEITC cannot be ruled out. When proliferative lesions associated with genotoxic and nongenotoxic compounds are compared, the former tended not to regress, in contrast to the case with the latter (19, 20) . In general, after multiple steps and accumulation of genetic alterations in oncogenes and/or tumor suppressor genes, carcinomas develop as irreversible lesions. p53 is one of the most commonly altered tumor suppressor genes in various cancers. Diverse degrees of its mutations have been reported in human (21) (22) (23) (24) and chemically induced rat (25) (26) (27) urinary bladder carcinomas. For the better understanding of urinary bladder carcinogenesis, analysis of whether PEITC-induced bladder cancers are associated with p53 mutations is thus clearly warranted.
To cast light on the mechanisms of PEITC urinary bladder carcinogenesis in rats, the present analysis of reversibility of urothelial proliferative lesions and the presence of p53 and H- Fig. 1 . Experimental protocol. Animals in Group 1 were given 0.1% PEITC in diet for 48 weeks and then were killed. Group 2 were given 0.1% diet for 32 weeks and the diet changed into control diet (basal diet containing 1% corn oil without PEITC). Animals in this group were killed at the end of 32 weeks, and 1, 3, 7 days and 16 weeks after changing to control diet. Group 3 was maintained with control diet throughout the experiment as a control group and animals were killed at week 32 and at week 48. j, 0.1% PEITC in diet; u, control diet; m, death 1 h after intraperitoneal injection of 100 mg/kg body wt of BrdU.
ras mutations in cancers induced in male F344 rats was conducted.
Materials and methods

Animals and chemicals
Five-week-old male F344 rats were obtained from Charles River Japan Inc., Atsugi, Japan, and maintained in the Experimental Animal Sciences Center, Nagoya City University Graduate School of Medical Sciences. They were randomly distributed three animals per cage on hardwood chip bedding in an environment-controlled room, at 23 Ϯ 2°C and 50 Ϯ 5% humidity with a 12 h light and dark cycle.
PEITC (purity Ͼ98%) was purchased from Tokyo Kasei Kogyo, Tokyo, Japan. To prepare a 0.1% PEITC diet, chemical was dissolved in corn oil (10 g/kg diet; 1%), and the solution was mixed with basal diet (Oriental MF; Oriental Yeast Co., Tokyo, Japan) using a cake mixer. For the control diet, 1% corn oil alone was admixed. The diets were prepared once per 2 weeks and stored at 4°C in the dark before use, being replaced twice a week. Food and tap water were available ad libitum. The use of animals in this study followed the Guidelines for the Care and Use of Laboratory Animals of Nagoya City University Medical School and was approved by the Institutional Animal Care and Use Committee.
Animal experimentation
The experimental protocol is shown in Figure 1 . At the age of 6 weeks, rats were randomized into three groups, consisting of 12, 36 and 18 rats, respectively. Animals in Group 1 were given 0.1% PEITC diet for 48 weeks and then killed. Group 2 rats received 0.1% diet for 32 weeks and then returned to control diet. Subgroups were killed at the end of 32 weeks, and 1, 3, 7 days and 16 weeks thereafter. Group 3 was maintained on a control diet throughout the experiment as a control, the animals being killed at weeks 32 or 48. Body weights and food consumption were recorded biweekly. All animals were given an intraperitoneal injection of bromodeoxyuridine (BrdU) (Sigma Chemical Co., St Louis, MO) at a dose of 100 mg/kg body wt 1 h before death. Rats were weighed and killed under ether anesthesia, the liver and kidneys being immediately excised, weighed and fixed in 10% buffered formalin solution. The urinary bladders were inflated with 10% buffered formalin before being immersed in the fixative. Then, they were cut in half and weighed after removal of inflated formalin. One slice from the liver, two slices from the kidneys, four pieces from the ureters and eight slices including tumors from the urinary bladder were routinely prepared and sections of tissue blocks were cut and stained with hematoxylin-eosin (H&E) for microscopic examination.
Histopathological analysis
Proliferative lesions were semi-quantitatively analyzed by measuring the length of the basement membrane of each lesion with the assistance of an image analyzer (VIP-21C, Olympus-Ikegami Tsushin Co., Tokyo, Japan) connected to a microscope. The ratios to the total length of the basement membrane were then calculated for each lesion. The Kruskal-Wallis test (non-parametric one-way analysis of variance) together with the Scheffe correction for multiple comparisons test and the latter alone were employed for statistical analysis of data for incidences and mean Ϯ standard deviation, respectively.
SSCP analysis
DNA samples were extracted from the unstained paraffin sections of the neoplastic lesions induced by the 48-week administration of PEITC, using DexPat (Takara, Ohtsu, Japan) following the manufacturer's instructions and additional ethanol precipitation. Nested PCR was performed for H-ras exons 1 and 2 and p53 exons 5-7 (it covers exons 5-8 of human homolog) with the primer sets listed in Table I . [α-P 32 ]dCTP (Amersham, Arlington Heights, IL) was added to the inner PCR solution and gel electrophoresis was performed with 0.5ϫ MDE gels (AT Biochem, Malvern, PA), with or without 5% glycerol. After drying, gels were autoradiographed with X-ray film. PCR products from the shifted bands were eluted, amplified with the same primer sets and sequenced by the Taq Dye Deoxy Terminator Cycle Sequence method (ABI PRISM, Applied Biosystems, Foster City, CA).
Results
PEITC at the dose given suppressed body weight gain~6-8% throughout the experiment, but after the withdrawal of PEITC administration at week 32, body weight gain slightly recovered (data not shown). Figure 2 illustrates the relative urinary bladder weights at the various time points of death in the three groups. Treatment with PEITC caused a significant increase and while discontinuation at week 32 resulted in a gradual decrease, in a duration-dependent manner, even after 16 weeks values were still significantly higher than normal.
Macroscopically, urinary bladders continuously treated with PEITC for 32 or 48 weeks became less translucent and thicker than control. Especially, 48 weeks administration caused roughening of the surface of the urinary bladder. Protrusion of tumors was not observed. The bladders, 16 weeks after withdrawal of PEITC treatment had discoid and irregular foci of thickening surrounded by thin mucosa.
Proliferative lesions of the urinary bladder were classified into simple hyperplasia, papillary or nodular (PN) hyperplasia, dysplasia and carcinomas, including transitional cell carcinomas with squamous cell and adenocarcinoma components (Table II) . Usually PEITC-induced tumors showed downward and nodular growth. In this experiment, no papillomas comparable with those induced by urinary bladder carcinogens such as BBN (28, 29) 
, N-[4-(5-nitro-2-furyl)2-thiazolyl]formamide
(FANFT) (30, 31) , or the combination of 3,2Ј-dimethyl-4-aminobiphenyl and butylated hydroxyanisole (32) were found. Dysplasia was characterized as slightly thickened urothelium with moderate cellular atypia, and frequent mitoses ( Figure  3A and C). Carcinomas were not found in rats killed 0, 1 or 3 days after withdrawal of PEITC-administration, but were noted in two of six rats killed after 7 days and in seven out of 12 after 16 weeks ( Figure 3B ). The latter incidence was statistically significant as compared with the negative control value. Continuous administration of PEITC for 48 weeks induced bladder carcinomas in 92% of the animals ( Figure 3C ).
In spite of a gradual decrease in bladder weights after discontinuation of PEITC administration, no decreases in the incidences of simple-and PN-hyperplasias were evident. The incidence of carcinomas rather increased, indicating progression of lesions in the absence of PEITC. In the control group, none of the rats developed such lesions. Quantitative data (Figure 4) showed the ratios of mucosa occupied by simple hyperplasia and PN hyperplasia to the entire length of mucosa to gradually decrease after withdrawal of PEITC insult. However, values for dysplasia and carcinoma were slightly increased. Figure 3D -F. LIs of carcinomas were the highest values among the lesions with decrease in the order of dysplasias, PN hyperplasias and simple hyperplasias. LIs of normal-looking epithelium in PEITC-treated rats were almost the same as those of simple hyperplasias and tended to be higher than in the control group. However, the LIs of hyperplasias and normal-looking epithelium dramatically dropped after the withdrawal of PEITC, whereas those of dysplasias and carcinomas demonstrated only limited reduction. Apoptotic bodies were not observed in the urothelium during the process of loss of hyperplastic lesions. No histopathological changes were noted in the liver, kidneys or ureters of any of the groups of rats.
The results of mutation analysis of H-ras and p53 genes in PEITC-induced urinary bladder carcinomas are summarized in Table IV . PCR and gel-electrophoresis were performed at least twice for each sample and loci and the mutations were determined when alteration was confirmed by the second test. A silent point mutation, ATC (Ile) to ATT (Ile), was found in codon 55 of H-ras exon 2 in one out of 12 tumor samples (8.3%). Seven out of 12 samples (58.3%) had mutations in p53, four in exon 5 and four in exon 7 ( Figure 5 ). Double mutations were found in one sample. Four of eight mutations in p53 were of silent point type. Five of nine mutations, including that found in H-ras, were C to T transitions. F) . Typical lesions corresponding with dysplasia and carcinoma were indicated by opened arrowhead , and closed arrow ., respectively. High LIs were seen in all lesions including simple HP, dysplasia, carcinoma during PEITC-administration (A, C, D, F). Carcinoma remained, but relatively large lesions returned to normallooking mucosa with low LI (B,E). Most of the urothelium was covered with hyperplasia and dysplasia, and carcinoma with high LI (C,F).
Discussion
PEITC has been regarded as a promising chemopreventive agent, as it potently inhibits carcinogenesis in the mammary glands, forestomach, esophagus and lung, mostly when given prior to or during exposure to carcinogen (3) (4) (5) (6) 8) . Recently, it was reported that in the post-exposure phase dietary administration of Nacetylcysteine conjugates of PEITC (at a dose of 0.98%, which is equal to 0.2% PEITC) also inhibited the development of benzo[a]pyrene-induced lung tumor in A/J mice (33) . However, the present study clearly demonstrated continuous administration of 0.1% PEITC to induce urinary bladder carcinomas, in line with our previous studies (13, 14) and the findings of Dunnick et al. (34) with allyl isothiocyanate, another isothiocyanate compound carcinogenic to the rat urinary bladder.
550
In general, reversible proliferative lesions do not feature multiple genetic alterations. Genotoxic compounds tend to induce not only reversible proliferative lesions (35) but also irreversible preneoplastic lesions from an earlier stage of carcinogenesis as compared with their non-genotoxic counterparts (20) . Reversibility of lesions on withdrawal of the inducing insult may therefore provide clues as to genotoxicity as well as the pathway from preneoplastic lesions to carcinoma. In the present study, irreversible dysplastic mucosal changes were observed with 32 weeks administration of PEITC. Within this period, genetic changes sufficient for carcinogenesis were presumably induced in the urothelium.
Early lesions induced by PEITC could be readily divided into two groups, one hyperplastic with little atypia, and the other dysplastic with many mitoses. The former disappeared after withdrawal of PEITC treatment in a time-dependent manner whereas the latter appeared to rather continuously 551 progress. Cell proliferative activity as reflected in the BrdU LI was also high in dysplasia during PEITC administration. Moreover, at 16 weeks after withdrawal of insult, the LI had decreased to one of 10 in hyperplastic lesions, but only a little more than half in dysplasia. The data suggest autonomy of the latter in line with a histogenetic role in development of malignancies.
Regarding possible mechanisms of carcinogenic action, in vitro formation of reactive oxygen intermediates in rat hepatocytes by a PEITC-related compound, benzyl isothiocyanate (BITC), has been demonstrated (36) . In vivo, PEITC and BITC have potent cytotoxicity, and induce cell proliferation of rat urinary epithelium in the early phase of administration (unpublished data). Furthermore, evidence of genotoxicity of PEITC itself has been accumulating from in vitro studies (16) (17) (18) . Especially isothiocyanates, including allyl isothiocyanate, BITC and PEITC, have been reported to cause Cu(II)-mediated DNA cleavage, frequently at thymine and cytosine in the DNA fragments from human p53 and c-Ha-ras, and formation of 8-oxo-7,8-dihydro-2Ј-deoxyguanosine in HL-60 cells (37) . In the present investigation, while only one of the PEITC-induced carcinomas had a point mutation (8.3%) in H-ras, such genetic alteration was frequent (58.3%) in the p53 gene. Although some carcinomas analyzed in this study were found to invade the submucosa, no association was evident with the presence of a p53 mutation and invasive growth was noted. Frequencies of p53 mutations in chemically induced rat bladder carcinomas have varied among studies. FANFT-induced carcinomas were found to have a low frequency (Ͻ7.4%) (25) compared with those caused by BBN (60 and 57%) (26, 27) . In our series the C to T transition (four out of eight) was the most common type. It is also found in human bladder cancers at high frequency (23) and cytosine has been considered a major target of DNA cleavage caused by isothiocyanates (37) .
In human bladder carcinomas, two types of growth are observed. One is the papillary non-invasive type, which is also typical of most chemically induced rat bladder carcinomas, observed with genotoxic BBN (28, 29) and FANFT (31, 38) , as well as the non-genotoxic uracil (39) . The other is the nonpapillary invasive type, which accounts for most mouse bladder cancers (29, 30, 40) . Two molecular pathways corresponding to the genesis of these two types have been proposed by Spruck et al. (24) . In their study, loss of heterozygosity of chromosome 9, where p16 ink4a /p19 ARF is located, was observed in 24 of 70 (34%) papillary transitional cell carcinomas (Ta tumors) but was present in only three of 24 (12%) CIS and dysplasia lesions. In contrast, only one of 36 (3%) Ta tumors had a p53 mutation, compared with 15 of 23 (65%) CIS and dysplasias and 25 of 49 (51%) muscle invasive tumors. Similar frequencies of p53 mutations in human invasive bladder cancers have in fact been described in several reports (21, 22) . The macroscopic as well as microscopic features of PEITC-induced rat urinary bladder carcinoma did not include papillary growth, which is mostly observed in rat bladder treated with other bladder carcinogens, but rather appeared as diffuse or nodularly thickening of urothelium with downward growth, commonly observed with mouse bladder carcinomas. Mutations in the p53 gene were frequently detected in this experiment but most of them were silent with no obvious hot spots or signature. These facts suggest that loss of functional p53 may not be required for the non-papillary growth of urothelium in this model.
In conclusion, PEITC is a rat urinary bladder carcinogen. While some of the early proliferative lesions induced by PEITC are reversible, dysplasia persists and has the potential to give rise to non-papillary carcinomas, indicating genetic changes for cancers are already induced by week 32. Also, it is suggested that PEITC-induced rat urinary bladder carcinoma develop through different pathways compared with their counterparts due to well-known bladder carcinogens such as BBN, FANFT and uracil.
